0001193125-26-193328.txt : 20260429 0001193125-26-193328.hdr.sgml : 20260429 20260429215738 ACCESSION NUMBER: 0001193125-26-193328 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20260429 FILED AS OF DATE: 20260429 DATE AS OF CHANGE: 20260429 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Wellington Biomedical Innovation Master Investors (Cayman) II L.P. CENTRAL INDEX KEY: 0001903360 ORGANIZATION NAME: STATE OF INCORPORATION: E9 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-43251 FILM NUMBER: 26919592 BUSINESS ADDRESS: STREET 1: 280 CONGRESS STREET CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 617-951-5000 MAIL ADDRESS: STREET 1: 280 CONGRESS STREET CITY: BOSTON STATE: MA ZIP: 02210 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Avalyn Pharma Inc. CENTRAL INDEX KEY: 0001540171 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 452463191 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 105 W FIRST ST. CITY: BOSTON STATE: MA ZIP: 02127 BUSINESS PHONE: (206) 707-0340 MAIL ADDRESS: STREET 1: 105 W FIRST ST. CITY: BOSTON STATE: MA ZIP: 02127 FORMER COMPANY: FORMER CONFORMED NAME: Genoa Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20120120 3 1 ownership.xml 3 X0607 3 2026-04-29 0 0001540171 Avalyn Pharma Inc. AVLN 0001903360 Wellington Biomedical Innovation Master Investors (Cayman) II L.P. false C/O WELLINGTON MANAGEMENT COMPANY LLP 280 CONGRESS STREET BOSTON MA 02210 false false true false Series C-1 Convertible Preferred Stock Common Stock 1064473 D Series D Convertible Preferred Stock Common Stock 211013 D Each share of Series C-1 Convertible Preferred Stock and Series D Convertible Preferred Stock (collectively, the "Preferred Stock") is convertible into Common Stock on a one-for-19.2417 basis at any time at the option of the holder and will automatically convert into the number of shares shown in Column 3 immediately prior to the closing of the Issuer's initial public offering. The Preferred Stock has no expiration date. Wellington Biomedical Innovation Master Investors (Cayman) II L.P., By: Wellington Management Company LLP, as Investment Adviser, /s/ Jennifer C. Boylan, Authorized Person 2026-04-29